Altered whole blood thrombin generation and hyperresponsive platelets in patients with pancreatic cancer

Willems, Ruth Anne Laura; Konings, Joke; Huskens, Dana; Middelveld, Harmen; Pepels-Aarts, Nicol; Verbeet, Lisa; de Groot, Phillip Gerrit; Heemskerk, Johan Willem Marie; ten Cate, Hugo; de Vos-Geelen, Judith; de Laat, Bas; Roest, Mark

doi:10.1016/j.jtha.2023.12.037

Cited by 1 publication

(2 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several molecular pathways are involved in tumor cell induced platelet aggregation (TCIPA) in pancreatic cancer [ 30 ]. A recent study showed that patients with PDAC had a faster onset of whole-blood thrombin generation and overall increased endogenous thrombin potential when compared to plasma [ 31 ]. Interestingly, patients with PDAC are associated with hyperresponsive platelets, which degranulate in a shorter time.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Pancreatic Cancer and Venous Thromboembolism

Prouse,

Mohammad,

Ghosh

et al. 2024

IJMS

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of all pancreatic cancers and is the most fatal of all cancers. The treatment response from combination chemotherapies is far from satisfactory and surgery remains the mainstay of curative strategies. These challenges warrant identifying effective treatments for combating this deadly cancer. PDAC tumor progression is associated with the robust activation of the coagulation system. Notably, cancer-associated thrombosis (CAT) is a significant risk factor in PDAC. CAT is a concept whereby cancer cells promote thromboembolism, primarily venous thromboembolism (VTE). Of all cancer types, PDAC is associated with the highest risk of developing VTE. Hypoxia in a PDAC tumor microenvironment also elevates thrombotic risk. Direct oral anticoagulants (DOACs) or low-molecular-weight heparin (LMWH) are used only as thromboprophylaxis in PDAC. However, a precision medicine approach is recommended to determine the precise dose and duration of thromboprophylaxis in clinical setting.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Interestingly, patients with PDAC are associated with hyperresponsive platelets, which degranulate in a shorter time. These parameters are associated with an increased risk of thromboembolic events [ 31 ]. Activated platelets secrete vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF).…”

Section: Resultsmentioning

confidence: 99%